- Home
- ETV vs HRMY Comparison
ETV vs HRMY Comparison
Compare ETV & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETV
- HRMY
- Stock Information
- Founded
- ETV 2005
- HRMY 2017
- Country
- ETV United States
- HRMY United States
- Employees
- ETV N/A
- HRMY N/A
- Industry
- ETV Investment Managers
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- ETV Finance
- HRMY Health Care
- Exchange
- ETV Nasdaq
- HRMY Nasdaq
- Market Cap
- ETV 1.7B
- HRMY 1.9B
- IPO Year
- ETV N/A
- HRMY 2020
- Fundamental
- Price
- ETV $14.31
- HRMY $26.87
- Analyst Decision
- ETV
- HRMY Strong Buy
- Analyst Count
- ETV 0
- HRMY 10
- Target Price
- ETV N/A
- HRMY $51.30
- AVG Volume (30 Days)
- ETV 252.5K
- HRMY 1.0M
- Earning Date
- ETV 01-01-0001
- HRMY 10-28-2025
- Dividend Yield
- ETV 8.75%
- HRMY N/A
- EPS Growth
- ETV N/A
- HRMY 58.41
- EPS
- ETV N/A
- HRMY 3.10
- Revenue
- ETV N/A
- HRMY $772,527,000.00
- Revenue This Year
- ETV N/A
- HRMY $19.94
- Revenue Next Year
- ETV N/A
- HRMY $16.65
- P/E Ratio
- ETV N/A
- HRMY $8.72
- Revenue Growth
- ETV N/A
- HRMY 17.74
- 52 Week Low
- ETV $11.05
- HRMY $26.26
- 52 Week High
- ETV $13.50
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- ETV 63.22
- HRMY 27.45
- Support Level
- ETV $14.06
- HRMY $26.56
- Resistance Level
- ETV $14.32
- HRMY $27.48
- Average True Range (ATR)
- ETV 0.13
- HRMY 1.01
- MACD
- ETV 0.01
- HRMY -0.25
- Stochastic Oscillator
- ETV 87.56
- HRMY 8.99
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.